Q4 2024 Holdings
Filed 2025-02-14 | 106 holdings | $5.3B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↑ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc(FHTX) | COM | 344174107 | $15.4M | 3,255,514 | 0.3% |
| Recursion Pharmaceuticals in(RXRX) | CL A | 75629V104 | $15.6M | 2,315,000 | 0.3% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $18.4M | 225,000 | 0.3% |
| Envista Holdings Corporation(NVST) | COM | 29415F104 | $19.6M | 1,018,415 | 0.4% |
| Septerna Inc(SEPN) | COM | 81734D104 | $19.7M | 861,814 | 0.4% |
| Cogent Biosciences Inc(COGT) | COM | 19240Q201 | $20.5M | 2,631,000 | 0.4% |
| Lantheus Hldgs Inc(LNTH) | COM | 516544103 | $21.5M | 240,218 | 0.4% |
| 10X Genomics Inc(TXG) | CL A COM | 88025U109 | $21.5M | 1,497,000 | 0.4% |
| Establishment Labs Hldgs Inc(ESTA)Put | COM | G31249108 | $23.0M | 500,000 | 0.4% |
| Mereo Biopharma Group PLC(MREO) | SPON ADS | 589492107 | $23.5M | 6,710,429 | 0.4% |
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $23.9M | 593,000 | 0.5% |
| CG Oncology Inc(CGON) | COM | 156944100 | $24.4M | 851,593 | 0.5% |
| Savara Inc(SVRA) | COM | 805111101 | $24.4M | 7,964,000 | 0.5% |
| Inmode LTD(INMD) | SHS | M5425M103 | $26.4M | 1,578,708 | 0.5% |
| Docgo Inc(DCGO) | COM | 256086109 | $30.5M | 7,195,956 | 0.6% |
| Bicara Therapeutics Inc(BCAX) | COM | 055477103 | $31.3M | 1,795,174 | 0.6% |
| Phreesia Inc(PHR) | COM | 71944F106 | $32.0M | 1,271,832 | 0.6% |
| DAY One Biopharmaceuticals I(DAWN) | COM | 23954D109 | $32.9M | 2,596,033 | 0.6% |
| Lantheus Hldgs Inc | NOTE 2.625%12/1 | 516544AB9 | $33.7M | $25,255,000 | 0.6% |
| Alnylam Pharmaceuticals Inc(ALNY) | COM | 02043Q107 | $34.2M | 145,191 | 0.6% |
| Disc Medicine Inc(IRON) | COM | 254604101 | $38.1M | 600,515 | 0.7% |
| Pharvaris N V(PHVS) | COM | N69605108 | $38.7M | 2,017,464 | 0.7% |
| Galapagos NV(GLPG) | SPON ADR | 36315X101 | $38.8M | 1,411,000 | 0.7% |
| Enhabit Inc(EHAB) | COM | 29332G102 | $39.1M | 5,010,972 | 0.7% |
| Cullinan Therapeutics Inc(CGEM) | COM | 230031106 | $41.2M | 3,379,399 | 0.8% |
| Conmed Corp(CNMD) | COM | 207410101 | $41.9M | 611,964 | 0.8% |
| Alphatec Hldgs Inc | NOTE 0.750% 8/0 | 02081GAB8 | $46.7M | $49,500,000 | 0.9% |
| BIO RAD Labs Inc(BIO) | CL A | 090572207 | $49.8M | 151,644 | 0.9% |
| Legend Biotech Corp(LEGN) | SPONSORED ADS | 52490G102 | $50.5M | 1,551,718 | 1.0% |
| Edgewise Therapeutics Inc(EWTX) | COM | 28036F105 | $55.5M | 2,078,509 | 1.1% |
| Baxter Intl Inc(BAX) | COM | 071813109 | $56.1M | 1,923,100 | 1.1% |
| Biocryst Pharmaceuticals Inc(BCRX) | COM | 09058V103 | $61.2M | 8,144,442 | 1.2% |
| Owens & Minor Inc New(ACH) | COM | 690732102 | $64.2M | 4,911,979 | 1.2% |
| Catalyst Pharmaceuticals Inc(CPRX) | COM | 14888U101 | $65.4M | 3,133,011 | 1.2% |
| Dynavax Technologies Corp(DVAX) | COM NEW | 268158201 | $66.3M | 5,193,823 | 1.3% |
| Embecta Corp(EMBC) | COMMON STOCK | 29082K105 | $67.5M | 3,270,535 | 1.3% |
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $70.3M | 2,736,000 | 1.3% |
| Brookdale SR Living Inc(BKD) | COM | 112463104 | $78.5M | 15,612,264 | 1.5% |
| Larimar Therapeutics Inc(LRMR) | COM | 517125100 | $82.2M | 21,231,974 | 1.6% |
| Alignment Healthcare Inc(ALHC) | COM | 01625V104 | $82.2M | 7,304,302 | 1.6% |
| Adapthealth Corp(AHCO) | COMMON STOCK | 00653Q102 | $92.5M | 9,711,410 | 1.8% |
| Mirum Pharmaceuticals Inc | NOTE 4.000% 5/0 | 604749AB7 | $106.6M | $70,000,000 | 2.0% |
| Indivior PLC(INDV) | ORD | G4766E116 | $110.4M | 8,883,160 | 2.1% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $110.9M | 4,314,340 | 2.1% |
| ARS Pharmaceuticals Inc(SPRY) | COM | 82835W108 | $110.9M | 10,514,657 | 2.1% |
| Alnylam Pharmaceuticals Inc | NOTE 1.000% 9/1 | 02043QAB3 | $117.3M | $110,000,000 | 2.2% |
| Neurocrine Biosciences Inc(NBIX) | COM | 64125C109 | $117.7M | 862,000 | 2.2% |
| Waystar Hldg Corp(WAY) | COM | 946784105 | $120.9M | 3,295,260 | 2.3% |
| Accolade Inc | NOTE 0.500% 4/0 | 00437EAB8 | $124.5M | $132,598,000 | 2.4% |
| Merus N V | COM | N5749R100 | $125.0M | 2,972,787 | 2.4% |